Needham & Company LLC reiterated their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a research note published on Monday,Benzinga reports. They currently have a $202.00 price objective on the biotechnology company’s stock.
A number of other brokerages have also commented on SRPT. StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Guggenheim lifted their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Evercore ISI reduced their price objective on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. Finally, Piper Sandler cut their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $178.71.
Get Our Latest Stock Report on SRPT
Sarepta Therapeutics Price Performance
Insider Activity at Sarepta Therapeutics
In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. This represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by company insiders.
Hedge Funds Weigh In On Sarepta Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of SRPT. CIBC Asset Management Inc boosted its holdings in Sarepta Therapeutics by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock valued at $339,000 after purchasing an additional 86 shares during the period. EP Wealth Advisors LLC grew its position in Sarepta Therapeutics by 2.1% during the second quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock worth $774,000 after buying an additional 103 shares in the last quarter. UMB Bank n.a. increased its stake in Sarepta Therapeutics by 36.0% during the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 138 shares during the period. Oppenheimer Asset Management Inc. raised its holdings in Sarepta Therapeutics by 3.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock valued at $557,000 after acquiring an additional 145 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in shares of Sarepta Therapeutics by 16.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company’s stock valued at $134,000 after acquiring an additional 155 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Further Reading
- Five stocks we like better than Sarepta Therapeutics
- Dividend Payout Ratio Calculator
- Sizing Up a New Opportunity for NVIDIA Investors
- How to Invest in Biotech Stocks
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- What is a Stock Market Index and How Do You Use Them?
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.